This article was originally published on The Limbic The anti-CD38Â mAb daratumumab (Darzalex) has received a positive recommendation from the...
Myeloma NZ
Chatham cancer survivor inspires multiple myeloma patients
This article was originally posted on Strathroy Age Dispatch Multiple myeloma was practically a death sentence when Joanne Ternovan was diagnosed....
Multiple Myeloma March tackles low awareness, boosts research
This article was originally published on TB Newswatch.com THUNDER BAY – Jerry Vanderwey went through months of unexplained rib and back pain before...
New partnership aims to advance predictive tests for multiple myeloma in Ireland
This was originally published by News Medical Life Sciences By combining genomic testing and next generation sequencing technology, a new...
Crohn’s and Colitis NZ patient support group requests your support
Dr. Richard E. Stein, Chairman of the Crohn’s & Colitis NZ Charitable Trust, has asked for our support to help share their petition for funding...
New myeloma study
DREAM​M 7 - A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belnatamab...
Drug Exposure, Disease Characteristics Not Linked to Increased Mortality Risk in Patients with Multiple Myeloma Who Contracted COVID-19
This post was originally published by Cure Specific disease characteristics of, and treatments for, multiple myeloma were not associated with...
Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma
This post was originally published by Targeted Oncology C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at...
Novel Agents Rouse Responses in Relapsed/Refractory Multiple Myeloma
This article was originally published by OncLive In just the past 5 years, incredible progress has been made in multiple myeloma, evidenced by the...
Despite COVID-19 limitations, fundraiser for multiple myeloma finds a way
This article was originally published on CBC 'We still had that sense of community happening out there anyway' Small but mighty groups of those with...
NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
This article originally published by PharmaTimes Online The National Institute for Heath and Care Excellence (NICE) has turned down NHS funding of...
Blood Cancer Awareness Month
This September, the International Myeloma Foundation (IMF) asks you to take part in a social media campaign to raise awareness about blood cancers,...